Literature DB >> 2931606

Presynaptic serotonin receptor-mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock.

G M Goodwin, R J De Souza, A R Green.   

Abstract

Ligand-binding studies have demonstrated two types of serotonin (5-HT) receptor, 5-HT1 and 5-HT2, in the brains of rodents and there is additional evidence for the existence of 5-HT1 subtypes. Recently a new drug, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), has been identified which shows high selectivity for binding to 5-HT1 (possibly 5-HT1A) receptors and which binds to presynaptic serotonin autoreceptors in some regions of rat brain. We have shown previously, that this compound produces a hypothermic response in mice, probably via an agonist action at serotonin presynaptic receptors. Here we show that a wide range of antidepressant treatments decrease the hypothermic response to 8-OH-DPAT over a time course comparable to the onset of therapeutic action. Interestingly, repeated electroconvulsive shock (ECS) has the same effect. We propose that this change is relevant to the mechanism of action of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931606     DOI: 10.1038/317531a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

1.  Hypothermia induced by baclofen, a possible index of GABAB receptor function in mice, is enhanced by antidepressant drugs and ECS.

Authors:  J A Gray; G M Goodwin; D J Heal; A R Green
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

2.  Effects of long-term administration of imipramine on reticular-elicited hippocampal rhythmical slow activity.

Authors:  X O Zhu; N McNaughton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

3.  Proceedings of the British Pharmacological Society. Bristol, 5-7th April. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1989-07       Impact factor: 8.739

Review 4.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

5.  Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.

Authors:  Cedric Mombereau; Tamar L Gur; Jennifer Onksen; Julie A Blendy
Journal:  Int J Neuropsychopharmacol       Date:  2009-12-14       Impact factor: 5.176

6.  Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression.

Authors:  Malika El Yacoubi; Saoussen Bouali; Daniela Popa; Laurent Naudon; Isabelle Leroux-Nicollet; Michel Hamon; Jean Costentin; Joëlle Adrien; Jean-Marie Vaugeois
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

7.  Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Margaret S Smith; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2003-05-01       Impact factor: 4.530

8.  Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations.

Authors:  J Maj; E Moryl
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats.

Authors:  Judith R Homberg; Sietse F De Boer; Halfdan S Raasø; Jocelien D A Olivier; Mark Verheul; Eric Ronken; Alexander R Cools; Bart A Ellenbroek; Anton N M Schoffelmeer; Louk J M J Vanderschuren; Taco J De Vries; Edwin Cuppen
Journal:  Psychopharmacology (Berl)       Date:  2008-06-27       Impact factor: 4.530

10.  Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.

Authors:  G P Luscombe; K F Martin; L J Hutchins; J Gosden; D J Heal
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.